Effect of glucagon-like peptide-1 agonists on ventricular tachycardia ablation outcomes

Back

ESC Professional Premium Access

Effect of glucagon-like peptide-1 agonists on ventricular tachycardia ablation outcomes

Session: New insights and management of ventricular arrhythmias in coronary artery disease

Topic: Drug Treatment of Ventricular Arrhythmias

Speaker: Doctor D. Zhang (Stony Brook, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor David Tianbai Zhang

Stony Brook University Hospital, Stony Brook (United States of America)

0 follower

6 more presentations in this session

Development and validation of the RISE-APOCALYPSE-VT risk score for predicting ventricular tachycardia/fibrillation in AMI

Speaker: Doctor K. Fierros-Chable (Mexico City, MX)

Impact of coronary chronic total occlusion revascularization on ventricular arrhythmias and cardiac death: a systematic review and meta-analysis

Speaker: Mr S. Su (Beijing, CN)

The impact of new-onset ventricular arrhythmias on prognosis after percutaneous coronary intervention

Speaker: Mr S. Su (Beijing, CN)

Development and validation of the MADIT-ICD benefit risk score for Japanese patients - from Nippon Storm study

Speaker: Associate Professor Y. Kondo (Chiba, JP)

Catheter ablation versus antiarrhythmic drugs in patients with ventricular tachycardia and ischemic cardiomyopathy: a meta-analysis of randomized controlled trials

Speaker: Mr D. Abraham (Manaus, BR)

Access the full session

New insights and management of ventricular arrhythmias in coronary artery disease

Speakers: Doctor D. Zhang, Doctor K. Fierros-Chable, Mr S. Su, Mr S. Su, Associate Professor Y. Kondo...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources